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Cholesterol-Iowering therapy with pravastatin in patients with
average cholesterol levels and established ischaemic heart disease:
is it cost-effective?
Paul P Glasziou, Simon 0 Eckermann, Sarah E Mulray, R John Simes, Andrew J Martin,
Adrienne C Kirby, Jane P Hall, Susan Caleo, Harvey 0 White and Andrew M Tonkin
Objective: To measure the cost-effectiveness of cholesterol-lowering therapy with
pravastatin in patients with established ischaemic heart disease and average baseline
cholesterol levels.
Design: Prospective economic evaluation within a double-blind randomised trial
(Long-Term Intervention with Pravastatin in Ischaemic Disease [LIPID)), in which
patients with a history of unstable angina or previous myocardial infarction were
randomised to receive 40mg of pravastatin daily or matching placebo.
Patients and setting: 9014 patients aged 35-75 years from 85 centres in Australia
and New Zealand, recruited from June 1990 to December 1992.
Main outcome measures: Cost per death averted, cost per life-year gained,
and cost per quality-adjusted life-year gained, calculated from measures of
hospitalisations, medication use, outpatient visits, and quality of life.
Results: The LIPID trial showed a 22% relative reduction in all-cause mortality
(P < 0.001). Over a mean follow-up of 6 years, hospital admissions for coronary heart
disease and coronary revascularisation were reduced by about 20%. Over this period,
pravastatin cost $A4913 per patient, but reduced total hospitalisation costs by $A1385
per patient and other long-term medication costs by $A360 per patient. In a
subsample of patients, average quality of lifewas 0.98 (where O=dead and 1=normal
good health); the treatment groups were not significantly different. The absolute
reduction in all-cause mortality was 3.0% (95% CI, 1.6%-4.4%), and the incremental
cost was $3246 per patient, resulting in a cost per life saved of $107730 (95% CI,
$68626-$209881) within the study period. Extrapolating long-term survival from the
placebo group, the undiscounted cost per life-year saved was $7695 (and $10938
with costs and life-years discounted at an annual rate of 5%).
Conclusions: Pravastatin therapy for patients with a history of myocardial infarction
or unstable angina and average cholesterol levels reduces all-cause mortality and
appears cost effective compared with accepted treatments in high-income countries.
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CORONARY HEART DISEASE is the
most common cause of death in devel-
oped countries. The past two decades
have seen improvements in therapy that
have led to declines in coronary heart
disease in countries such as the United
States and Australia, with much of this
decline being attributable to improve-
ments in care of patients with estab-
lished disease. 1 These improvements
include immediate treatment of myo-
cardial ischaemia, such as thrombolytics
and aspirin, and better control of risk
factors, such as blood pressure, smok-
ing, and cholesterol. The use of 3-
hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors has
been established as the most important
means of reducing the toll from hyper-
cholesterolaemia. The Scandinavian
Simvastatin Survival Study (4S) showed
a 30% reduction in the risk of death at a
median follow-up of 5.4 years in a
group of patients with established coro-
nary heart disease and elevated choles-
terol levels (5.5-8.0 mmol/L)." More
recently, the Cholesterol and Recurrent
Events (CARE) triaf and the Long-
Term Intervention with Pravastatin in
Ischaemic Disease (UPID) trial" have
shown that this advantage also applies
to patients with established coronary
heart disease and average cholesterol
levels (4.0-7.0 mmoVL).
At the same time as these advances in
therapy, health expenditure has
increased, particularly for pharmaceuti-
cal products, and a consequence is con-
cern with controlling rising costs. Those
who pay for health services increasingly
ask about the benefits received for
resources invested, either informally or
through processes such as cost-effec-
tiveness analysis.l The governments of
Australia and Ontario (Canada) have
taken this furthest by requiring infor-
mation on economic outcomes to assist
decisions on subsidising new pharma-
ceutical products.
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To answer the question whether prava-
statin is economically worthwhile for
patients with established coronary heart
disease and "average" cholesterol levels,
we undertook a prospective cost-effec-
tiveness analysis within the UPID trial
of pravastatin. The results of the main
study and the protocol for the cost-
effectiveness component have been
published.v" In this article, we report
the differences in use of resources and
quality of life between the pravastatin
and placebo groups, and the cost-effec-
tiveness of pravastatin versus placebo
for the population of patients in the
UPID trial.
MEllIODS
The UPID trial was a double-blind,
randomised, placebo-controlled trial
evaluating the long-term effects of prava-
statin on all-cause mortality and coro-
nary disease mortality in patients who
had had unstable angina or an acute
myocardial infarction, and had a total
cholesterol level of 4.0-7.0 mmol/L.
The trial involved 9014 patients at 85
centres in Australia and New Zea-
land.4,6 Patients were given dietary
advice conforming with the National
Heart Foundation's recommendations
and randomly assigned to receive 40 mg
of pravastatin or placebo daily. Patients
were recruited between June 1990 and
December 1992, and follow-up was to
be at least five years.
The cost-effectiveness substudy
aimed to estimate the cost per death
averted, the cost per life-year gained,
and the cost per quality-adjusted life-
year gained. The data requirements
were broken down into four major ele-
ments:
• survival to the end of the study, as
estimated by Kaplan-Meier curves,
with extrapolation for the estimates of
life-years and quality-adjusted life-years
gained;
• measurements of quality of life,
including work capacity;
• resource use by patients (inpatient
and outpatient services, including hos-
pitalisations, healthcare visits, diagnos-
tic tests, and long-term medication);
and
• prices and costs for each of the
resources used.
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Data on survival and hospitalisations
were collected as part of the main
UPID study. To obtain the additional
information required to ascertain cost-
effectiveness, several sub studies were
established. Only the direct costs of
healthcare were included, reflecting a
health care perspective following the
Australian Pharmaceutical Benefits
Advisory Committee guidelines," Costs
are reported in 1998 Australian dollars.
Resource use
All hospitalisations were included and
assigned a cost based on the diagnosis-
related group category and length of
stay.? Data on long-term (out-of-hospi-
tal) medication use were collected as
part of the main study, with information
about dosage being collected for a sepa-
rate subgroup (n = 1100). These two
sources were combined to estimate total
medication use. Drugs were sorted by
absolute difference in a month's use
(between pravastatin and placebo) and
costed until the sum of the absolute cost
difference in the last five drugs contrib-
uted less than 1% of a cumulative cost
difference. For the 91 drugs identified
for costing in this way, average doses
and frequency of use per month were
estimated from the combined-arm sub-
study of 1100 patients and applied to
reported months used to estimate total
use in each arm. Sub studies of resource
use by treatment arm were undertaken
for outpatient visits to doctors and other
healthcare professionals in the quality-
of-life cohort of 1112 patients; use of
diagnostic tests in a sample of 485
patients at one, three and five years'
follow-up; and nursing home costs, esti-
mated for all 330 patients who experi-
enced stroke and consequently stayed in
nursing homes.
For outpatient visits and diagnostic
tests, as substudies were based on a
sample rather than the full cohort, the
common average resource use per
patient was inferred, unless there were
statistically significant differences by
treatment arm in sampled average use.
We adjusted the costs of sampled
resource use for survival differences
between treatment arms.
In the cost-effectiveness analyses, unit
costs of resources were allocated as pre-
scribed by the Australian Pharmaceuti-
cal Benefits Scheme's manual of costs
used for cost-effectiveness analyses."
Principally, the sources were diagnosis-
related group costs for hospitalisations;
the Australian Medicare Benefits
Schedule" for outpatient visits and out-
patient diagnostic testing; and the
schedule of pharmaceutical benefits'?
for the costs of medications. Data on
average daily dosage from community
samples were compared with the sub-
study medication dosage information to
confirm that UPID patients were simi-
lar to a community sample.
The quality-of-life data were obtained
from a subcohort of 1112 patients given
questionnaires at baseline, and one,
three and five years later. The question-
naire was the utility-based quality-of-life
questionnaire (UBQ-H), a modification
of the York Health Measurement Ques-
tionnaire, which was extended to
include questions on cardiovascular
symptoms and a self-completed time
trade-off question. 11,12
AnalysIs
The analysis used an intention-to-treat
principle for both effects and costs. This
required that resource use was counted
according to a patient's initial randomi-
sation, whether or not he or she contin-
ued study medication. Thus, for
patients on placebo who "dropped in"
by commencing a cholesterol-lowering
agent, all medication costs, including
the costs of statins, were attributed to
the placebo group. Similarly, pravastatin
in the active group was costed on an as-
dispensed basis. Analogous to the inclu-
sion of all-cause mortality as an out-
come, all hospitalisation costs
(cardiovascular and non-cardiovascular)
were included.
Ninety-five percent confidence inter-
vals for incremental costs (the differ-
ence in costs between a pravastatin and
placebo patient) were calculated from
individual patient total costs, where
available, for pravastatin, other medica-
tion and hospitalisations. Other incre-
mental costs were considered constant
and included as such in the 95% CIs for
total incremental costs. A 95% CI for
ratios of incremental cost per life saved
were estimated from bootstrapping the
incremental cost-effectiveness ratio dis-
tribution following the method of Briggs
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1: Hospitalisations, length of stay and hospital costs of patients in the LIPID study, according to treatment group*
Average cost per
Hospital admissions Average stay (days) admission' ($A) Total cost' ($A)
Reason for hospitalisation Placebo Pravastatin Placebo Pravastatin Placebo Pravastatin Placebo Pravastatin
Coronary-artery bypass surgery 498 405 14.4 12.2 12165 11209 6058346 4539444
Unstable angina 1463 1258 4.6 4.3 2471 2452 3614475 3084553
Myocardial infarction 450 338 8.6 8.6 4873 4941 2192656 1 669896
Angioplasty 331 240 5.9 5.4 4910 4795 1625056 1 150707
Stroke 140 113 18.6 16.1 7273 6608 1018157 746758
Other circulatory disorder 2916 2617 5.0 4.5 3329 3130 9706152 8192416
Diseases and disorders of the respiratory system 796 713 6.7 6.9 3316 3285 2639317 2342095
Diseases and disorders of the skin. subcutaneous t~sue 456 469 5.5 39 2570 1922 1 171845 901634
and breast
Diseases and disorders of the digestive system 1527 1447 3.8 3.9 2185 2142 3335811 3099966
Neoplastic disorders (haematological and solid 152 142 10.6 6.2 4678 3376 711020 479458
neoplasms)
Mental diseases and disorders 68 58 22.2 19.7 6814 4665 463383 270584
Diseases and disorders of blood and blood-forming 174 72 2.8 2.9 1275 1211 221803 87203
organs, and immunological disorders
Injuries. poisoning and toxic effects of drugs 97 94 7.9 5.6 3770 2677 365683 251 678
Infectious and parasitic diseases (systemic, 105 87 9.1 6.9 4935 4655 518175 404991
or unspecified site)
Diseases and disorders of the female reproductive 73 104 5.3 6.1 2586 2843 188755 295629
system
Diseases and disorders of the musculoskeletal system 872 894 7.3 7.2 5185 5220 4521607 4666249
and connective tissue
Diseases and disorders of the male reproductive system 472 510 4.6 4.8 2595 2722 1224829 1 388468
Other 2194 2148 5.9 5.1 3055 3054 6702061 6560544
Total 12784 11709 46279131 40132270
•Pravastatin group: n= 4512. Placebo group: n= 4502. tAdjusted for long length-of-stay outliers according to casemix standards for NSW 1997-1998.'
et al,13 using individual patient's cost
and effect pairs, by treatment arm, in
10 000 bootstrap replications. A con-
stant incremental cost was included for
outpatient visits, diagnostic tests and
nursing home substudy costs. The same
bootstrap replications were also used to
estimate a 95% CI for absolute risk
reduction in all-cause mortality.
RESULTS
From June 1990 until December 1992,
9014 patients (5958 from Australia and
3056 from New Zealand) from 85 cen-
tres were randomly allocated to prava-
statin or placebo. Baseline characteris-
tics were well balanced in the two
groups. The qualifying event was acute
myocardial infarction in 64%, and
unstable angina in 36%, with 12% hav-
ing had both qualifying events (they
were included in the myocardial infarc-
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tion stratum). Of the patients, 17%
were women, and 32% had had coro-
nary revascularisation surgery. Their
average cholesterol levels were
5.65 mmollL (total), 3.88 mmollL
(low-density lipoprotein [LDL)), and
0.92 mmollL (high-density lipoprotein
[HDL)). The mean follow-up period
was 6.0 years; during this time, 23.8%
of patients on placebo commenced cho-
lesterol-lowering therapy (drop-ins),
and 18.9% of patients on pravastatin
therapy discontinued (drop-outs), of
whom 22% went on to another choles-
terol-lowering agent.
The cumulative all-cause mortality in
the placebo group was 14.1%, and in
the pravastatin group was 11.0%, repre-
senting a relative reduction of 23%
(P < 0.00 1). This included a 25% rela-
tive reduction in cardiovascular deaths
(P < 0.001), a 24% reduction in coro-
nary deaths (P< 0.001), and no differ-
ence in death rates for non-
cardiovascular causes. The rates of non-
haemorrhagic stroke were 4.4% in the
placebo group and 3.4% in the prava-
statin group, a relative reduction of23%
(P= 0.02).
Hospital costs
Hospitalisation rates, average unit costs
for each admission type, and costs
adjusted for long length-of-stay outliers
according to casemix standards for New
South Wales 1997-19987 are shown in
Box 1.
Pharmaceutical costs
The costs of pravastatin dispensed to
the treatment group over the entire trial
period were based on a single 40 mg
tablet per day, which currently costs
$80.30 (Australian dollars) for 30 days'
supply on the Pharmaceutical Benefits
Scheme. The equivalent cost in the
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(patient-months) Cost ($A) pravastatin
Medication Pravastatin Placebo Pravastatin Placebo group ($A)
All (non-pravastatin) 290427 1487466 -266
cholesterol-lowering drugs
Statins 4347 22550 213610 1110378 -199
Fibrates 1456 6065 55180 204476 -33
Resins 228 2127 15940 150341 -30
Others 395 618 5697 22271 -4
All cardiovascular drugs 7678605 7926424 -59
(other than cholesterol-
lowering)
Angiotensin-converting 63998 65574 2070202 2121 637 -12
enzyme inhibitor
Antianginal drug 116557 121091 2872 871 2987187 -27
~-Blocker 56169 58931 526784 529935 -1
Diuretic 48138 55740 172683 203731 -7
Calcium-channel blocker 52994 55223 1 198762 1 249916 -12
Other cardiac drug 306649 302512 837303 834018 0
Other drugs 2438697 2593381 -36
Respiratory system drugs 35182 40817 336152 410065 -17
Gastrointestinal system 31966 33958 912615 980709 -16
drugs
Musculoskeletal system 54947 51517 432427 415299 4
drugs
Psychoactive drugs 18145 19809 213048 240692 --6
Others 66844 67174 544455 546616 -1
Total 10407729 12007271 -360
•Pravastatin group: n= 4512. Placebo group: n= 4502.
United Kingdom is £31.80 and, in the
United States, is $US96.32 (average US
wholesale price reduced by 18.3% to
reflect that it overestimates actual phar-
macy acquisition costs). The 4512
patients used pravastatin for an average
of 61.2 months (of the 73 months of
follow-up), resulting in an average cost
of $4913 per patient. Some other medi-
cation costs differed between the two
groups (Box 2). Because of the drop-ins
to cholesterol-lowering therapy, the pla-
cebo group used more cholesterol-low-
ering agents (apart from study
pravastatin) than the pravastatin group.
Furthermore, rates of use of some other
cardiovascular agents, such as glyceryl
trinitrate, nifedipine and metoprolol,
were also higher in the placebo group.
The net difference in cost for drugs
other than pravastatin was $360, repre-
senting a 7% cost offset for the cost of
pravastatin.
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Outpatient, diagnostic test and nursing
home costs
Average resource use did not differ sig-
nificantly between the placebo and
pravastatin groups for ambulatory care
(sample of 1112 patients) or diagnostic
tests (sample of 485 patients). When the
costs of common resource use were
extrapolated to allow for survival differ-
ence by treatment arm, the incremental
costs for the pravastatin group were $45
per person for outpatient visits and $13
for diagnostic tests over the study period
(Box 3).
Although there were fewer nursing-
home stays after stroke among patients
in the pravastatin group than the pla-
cebo group (181 v 149), longer average
nursing-home stays in the pravastatin
group (49.1 v 37.9 days) resulted in
greater costs over the study period,
equivalent to $21 per person (Box 4).
Time off work
Patients in the quality-of-life subs ample
of 1112 patients were asked about their
work status at the time of randomisation
and one, three and five years later. The
proportions in work at baseline were
38% and 36% in the placebo and prava-
statin groups, respectively, and after five
years were 28% and 26%, respectively.
The differences were therefore small
and not significant.
Qualfty of life
Quality of life, as measured in the sub-
sample of 1112 patients, was generally
high in both groups, with fatigue,
insomnia and anxiety being the most
commonly reported problems. Based on
the UBQ-H questionnaire, the sum-
mary utility score in survivors was 0.98
(where 0 = dead and 1 = normal good
healthj.l" with a slight decline over time
but no statistically significant difference
between the pravastatin and placebo
groups (Box 5). Therefore, we did not
adjust life-years for quality differences.
Costs and cost-effectiveness
Box 4 summarises the information on
costs of resource use for the pravastatin
and placebo groups, and the cost differ-
ences between the groups. The total
cost difference, excluding the study
medication, was $1667 per patient in
favour of pravastatin. This represents a
one-third cost offset against the $4913
average cost per patient of pravastatin.
At the trial close, the absolute difference
in all-cause mortality was 3.0% (95%
CI, 1.6%-4.4%), and the net cost dif-
ference was $3246 (95% CI, $2638-
$3855) per patient (Box 4). The cost
per death prevented during the trial was
$107730, with a 95% CI from boot-
strapping of $68 626-$209 881. A one-
way sensitivity analysis on cost per life
saved using 95% CIs for cost and effect
factors (Box 6) indicated that the cost
per life saved was most sensitive to
uncertainty in absolute all-cause mor-
tality.
The mean follow-up period was 6.0
years.Within this period, the "extra survi-
vors" attributable to pravastatin treatment
will have gained between zero and six
years, with an average gain of three years.
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All visits to medical practitioner
Diagnostic tests per person
in 18 months (n=485)
Cardiac investigations
Radiology
Imaging other than radiology
Pathology tests




























•Based on substudies of patients assessed at 1, 3 and 5 years after randomisation. Diagnostic tests were
reported over the previous 6 months. doctor visits over the previous 2 weeks.
tAverage number of visits or tests per person summed over the 3 sample periods for combined pravastatin
and placebo groups (P> 0.10 in all cases).
:j:Average unit cost of each visit and test.
§Extra costs attributable to greater survival in pravastatin arm over the 6.0 years of the study, with common
average resource use per person applied.
4: Summary of resource costs and cost differences between pravastatin
and placebo groups
Total costs in each group ($A) Extra cost per
person in prava-
Resource Pravastalin (n=4512) Placebo (n=4502) statin group* ($A)
Hospital use 40132270 46279131 -1385
Cardiovascular' 19524071 24360241 -1084
Other than cardiovascular 20608198 21 918890 -301
Medications 10407729 12007273 -360
Cholesterol-lowering 290427 1 487466 -266
Other cardiovascular 7678605 7926424 -59
Other 2438697 2593381 -36
Ambulatory care 17 109639 16871056 45
Diagnostic tests 5011 405 4940859 13
Nursing home 783450 689449 21
Total costs other than pravastatin 73444493 80787768 -1667
Pravastatin for study 22166895 0 4913
Total 95611388 80787768 3246
• Includes all diseases and disorders of the circulatory system, plus heart transplant and stroke.
5: Utility scores* on the quality-of·life questionnaire in a subsample of
1112 patients over five years, by treatment group











'On a scale from O=dead to 1=normal good health.
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To calculate survival beyond the six-year
follow-up of the trial, we constructed a life
table of the 4502 patients on placebo. At
the end of the study, the median age of
the patients was 68 years (mean, 66.9
years), for which the within-trial life table
provides a further life expectancy of 11
years (compared with the general Austral-
ian population expectation of 12.7 years
for males and 16.2 for females). If the
survival curves do not further diverge and
no further costs are accrued, the expected
cost per life-year saved (undiscounted) is
$107730/(3.0+11) = $7695. This simple
projection assumes that the cost reduc-
tions from the healthier pravastarin group
and the costs incurred by the additional
survivors are roughly equal. It also ignores
any additional survival benefit that may
accrue among those who have avoided a
cardiovascular event (eg, strokes avoided) .
If future costs and benefits are both
discounted (to account for their lesser
value than current costs and benefits) at
the standard rate for Australian cost-
effectiveness analyses of 5% per year,
following Pharmaceutical Benefits
Advisory Committee guidelines," the
total cost difference becomes $2943 per
patient. Within the 6.0-year trial period,
the discounted time gained with prava-
statin was 2.7, rather than 3.0, years per
extra survivor, and the within-trial life
table provides a further life expectancy
of 6.2 discounted years. If the survival
curves do not further diverge, and no
further costs are accrued, the expected
cost per life-year saved (discounted at
5%) is $10938. Considering other
plausible survival effects beyond the
study, if within-study treatment effects
are prolonged or reversed for six years
beyond the study period the discounted
incremental life-years accrued would
increase by roughly 50% or halve,
respectively. Again, assuming no further
cost are accrued, this would result in a
cost per discounted-life-year saved of
about $7000 for a continued treatment
effect and $22 000 for reversal of the
treatment effect.
DISCUSSION
The results from the LIPID study show
that treatment with pravastatin in
patients with established coronary heart
disease and "average" cholesterol levels
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is effective in reducing mor-
tality. This cost-effectiveness
analysis shows that there is a
cost offset of roughly a third
of the total costs of pravasta-
tin dispensed during the
trial. The resultant cost-
effectiveness of $107 730
per premature death pre-
vented, or about $10 900
per discounted life-year
saved, is within a range gen-
erally considered acceptable
and is comparable with that
of many other interventions.
Treatment was cost-effec-
tive across a number of
assumptions, but was most
sensitive to any prolonged
treatment effect (or reversal)
beyond the six years. We are
therefore continuing to fol-
low up the UPID patients to
eventually provide more reli-
able long-term estimates of
cost-effectiveness. The
results at eight years suggest
that the treatment effect
continues. 14
How did these results
compare with those of other
analyses? Analyses of the
cost-effectiveness of statins
in cholesterol-lowering ther-
apy are difficult to compare
because of differences in the popula-
tions, healthcare practices, and cost per
unit of resources. Therapy for high-risk
groups, such as those with established
disease and high cholesterol levels, will
generally be more cost-effective because
the absolute benefits will be greater and
the cost offsets larger, whereas primary
prevention for patients with moderate
cholesterol levels and few other risk
factors will be the least cost-effective. In
this regard, it is interesting to compare
these results with the cost-effectiveness
found in the Scandinavian Simvastatin
Survival Study (4S).15 That study
showed a cost-effectiveness ratio that
ranged from $3800 to $27 400,
depending on the patient group. The
studies are difficult to compare because
of differences in the operation of health
services in the two countries. However,
the patients in 4S were at high risk, and
we would therefore expect greater cost-
effectiveness because of the greater
G: Sensitivity of incremental cost per life saved
to 95% Cis of costs and survival effects
co
~0.
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'Includes an incremental fixed cost of $79 for outpatient diagnostic test and
nursing home costs. tAbsolute risk reduction for all-cause mortality. :j:On a
baseline of $107 730. §The bootslrapped 95% CI for incremental cost per life
saved included uncertainty for all survival effects. and hospitalisation, pravastatin










absolute mortality difference. Previous
modelled analysis in the United King-
dom suggested a somewhat worse cost-
effectiveness than that seen in UPID:
for example, the cost-effectiveness for
men aged 45-60 with a history of myo-
cardial infarction and a cholesterol level
of 5.5-6.0 mmol/L was £16000 (dis-
counted at 5%).16
How then can we apply this result?
The absolute benefit is unlikely to be
substantially influenced by country-spe-
cific factors, and, given a roughly similar
price for pravastatin, the cost offsets are
unlikely to change sufficiently to provide
complete payment for pravastatin. Thus,
at worst, the cost per life-year saved may
be 50% higher than calculated (if there
were no cost offsets) or may be some-
what lower depending on country-spe-
cific costings. However, this is still likely
to leave it in a cost-effective range. To
confirm this, modelling of country-
specific cost-effectiveness is required.
The cost-effectiveness esti-
mates do not necessarily gen-
eralise from the trial to the
community. The extent of
generalis ability will depend
on factors such as relative-risk
profiles and compliance.!?
However, of perhaps more
importance will be modelling
the cost-effectiveness within
particular subpopulations to
answer the question, "Which
(if not all) patients with




ses show similar relative-risk
reductions across different
age, sex, and lipid-profile
groupings. Absolute risk, and
hence cost-effectiveness, will
therefore depend largely on
individual predicted risk .
Appropriate models for such
risk prediction in secondary
prevention are being devel-




statin is likely to be acceptably
cost-effective for most
patients with established cor-
onary artery disease,
Despite the mounting evidence on the
value of statin therapy, long-term ther-
apy with statins is still underused in
patients with coronary heart disease.
The Australian Pharmaceutical Benefits
Scheme's guidelines should be relaxed
so as not to require a trial of diet
therapy before statin therapy is com-
menced. The UPID trial has shown
that statin therapy is cost-effective when
given in addition to dietary advice. The
guidelines should allow statin therapy
and dietary treatment to start at the
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